Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicinal cannabis oil ratios for recurrent glioblastoma multiforme
ACTRN12617001287325Phase 2Completed
- Sponsor
- Endeavour College of Natural Health
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cannabidiol and dronabinol in glioblastoma (GBM), sponsored by Endeavour College of Natural Health. Primary endpoint: Change in quality of life by FACT-Br from baseline to week 12 between cannabis ratio groups. Started Nov 2018; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12617001287325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001287325.